Dillon & Associates Inc. Acquires 1,436 Shares of Intuitive Surgical, Inc. $ISRG

Dillon & Associates Inc. lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.3% during the third quarter, Holdings Channel.com reports. The fund owned 28,474 shares of the medical equipment provider’s stock after buying an additional 1,436 shares during the period. Intuitive Surgical accounts for approximately 1.6% of Dillon & Associates Inc.’s holdings, making the stock its 19th largest holding. Dillon & Associates Inc.’s holdings in Intuitive Surgical were worth $12,728,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Norges Bank acquired a new stake in Intuitive Surgical in the 2nd quarter valued at about $2,569,260,000. Vanguard Group Inc. grew its holdings in Intuitive Surgical by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock valued at $18,115,025,000 after buying an additional 670,302 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Intuitive Surgical by 20.4% in the second quarter. Jennison Associates LLC now owns 3,122,390 shares of the medical equipment provider’s stock valued at $1,696,738,000 after acquiring an additional 528,359 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of Intuitive Surgical by 89.3% during the second quarter. Bessemer Group Inc. now owns 788,328 shares of the medical equipment provider’s stock worth $428,386,000 after purchasing an additional 371,806 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in Intuitive Surgical by 25.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,582,280 shares of the medical equipment provider’s stock valued at $859,827,000 after acquiring an additional 317,324 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the subject of several analyst reports. Piper Sandler boosted their target price on shares of Intuitive Surgical from $595.00 to $610.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Rothschild & Co Redburn upped their price objective on Intuitive Surgical from $610.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. HSBC raised their target price on Intuitive Surgical from $595.00 to $644.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Wall Street Zen downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Daiwa Capital Markets upped their target price on Intuitive Surgical from $510.00 to $550.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $622.17.

Insider Activity

In other news, SVP Mark Brosius sold 464 shares of Intuitive Surgical stock in a transaction on Monday, December 15th. The stock was sold at an average price of $548.49, for a total transaction of $254,499.36. Following the sale, the senior vice president directly owned 131 shares in the company, valued at $71,852.19. The trade was a 77.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Craig H. Barratt sold 750 shares of Intuitive Surgical stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $435,000.00. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 114,007 shares of company stock worth $63,533,844. 0.70% of the stock is owned by insiders.

Intuitive Surgical Stock Down 1.0%

Shares of NASDAQ:ISRG opened at $541.34 on Friday. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The stock has a market cap of $194.06 billion, a price-to-earnings ratio of 71.61, a PEG ratio of 4.44 and a beta of 1.67. The business’s 50 day moving average is $566.82 and its 200 day moving average is $512.30.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.41. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm’s revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm earned $1.84 earnings per share. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 results beat expectations: procedure volume, system placements and revenue all grew, and management raised full‑year revenue guidance vs prior consensus—evidence of demand strength. Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Industry analysts reiterated buy/supportive views: Bernstein kept a Buy rating and William Blair reiterated bullish sentiment citing DV5 adoption and pipeline, which supports longer‑term growth expectations. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Company commentary and industry coverage note da Vinci systems “exceeded expectations” in procedures and placements, underlining the platform’s commercial traction. Intuitive says daVinci systems ‘exceeded expectations,’ it wants more
• Neutral Sentiment: IS‑001 Phase 3 update (imaging‑driven safety product) is in progress — relevant for the pipeline but uncertain timing/impact on revenue; watch trial readouts. IS-001 Phase 3 Update
• Neutral Sentiment: da Vinci 5 international rollout is expanding but faces pricing, budget and reimbursement hurdles overseas — a mixed catalyst: growth potential but adoption risk outside the U.S. da Vinci 5 Expands Globally
• Negative Sentiment: Management set a softer 2026 outlook and lowered its expected da Vinci growth cadence for the year, which overshadowed the Q4 beat and prompted the pullback as investors re‑price growth expectations. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Market reaction focused on a missed/tepid 2026 da Vinci growth projection despite solid quarterly results — traders viewed this as evidence of near‑term deceleration. da Vinci Growth Projection Misses Expectations
• Negative Sentiment: Commentary across outlets: “shares fell despite beating Q4” highlights investor sensitivity to forward guidance and valuation (high PE multiple); this sentiment amplified the decline. Why Intuitive Surgical Stock Is Falling Today

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.